Medical International Technology Continues Restructure, Forms Two Operating Divisions, Acquires ScanView and Completes Another Private Placement


DENVER, Dec. 22, 2005 (PRIMEZONE) -- Medical International Technology, Inc. ("MIT") (OTCBB:MDLH) (http://www.mitcanada.ca) reports that, as part of its continuing restructuring program, MIT is forming two divisions. The Human Medical Technology Division will focus on the development, production, marketing and sale of needle-free injectors and other medical technologies for humans. The Animal Medical Technology Division will deal with all aspects of the development, production, marketing and sale of the needle-free injectors and other technologies for animal applications worldwide.

MIT Acquires Portable Ultrasound Company "ScanView"

MIT is proceeding with the acquisition of ScanView, a Montreal-based portable ultrasound technology and manufacturing company. ScanView was formed in 2003 to develop, manufacture and market different models of Real Time Ultrasound Scanners, for Animal and Human applications. Management combines over 30 years experience and expertise in the development, production, marketing and sales of state-of-the-art, innovative and unique Real Time Ultrasound Scanner Technology.

ScanView has a unique, portable and battery operated ultrasound diagnostic medical device, using a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

Karim Menassa, President and CEO of Medical International, states, "We believe ScanView has the most powerful, smallest and lightest ultrasound diagnostic system in the world, combining features that no other system in its category has, making ScanView the leader in the technology in its field." Further information is available at www.scanview.ca.

MIT Closes Additional Private Placement Financing

MIT has closed another private placement. This is in addition to the two financings reported on December 7. This placement consists of 1,000,000 units at a price of $0.60 per unit for an aggregate investment of $600,000. Each unit includes one warrant for a total of 1,000,000 shares at a price of $0.75 per share. Including the private placements announced December 7, the funds raised since the beginning of the corporate restructure in October total $1,406,000.

MIT CANADA, with offices in Montreal, is a subsidiary of Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass inoculations.



 Karim Menassa, President
 On Behalf of the Board of Directors

The statements which are not historical facts contained in this news release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K Medical International Technology, Inc. takes no obligation to update or correct forward-looking statements.

This news release is available on the Medical International Investor Relation's site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com/IR/MIT. Alternatively, investors can e-mail their questions or comments directly to MDIR@agoracom.com or asked to be placed on the Medical International Technology investor e-mail list to receive all future news releases directly.



            

Contact Data